SevenBridge Financial Group LLC lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 2.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 39,481 shares of the company’s stock after purchasing an additional 1,041 shares during the quarter. Merck & Co., Inc. makes up about 1.3% of SevenBridge Financial Group LLC’s holdings, making the stock its 17th biggest position. SevenBridge Financial Group LLC’s holdings in Merck & Co., Inc. were worth $2,396,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in MRK. Oppenheimer Asset Management Inc. increased its stake in shares of Merck & Co., Inc. by 2.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 298,146 shares of the company’s stock worth $16,239,000 after purchasing an additional 7,353 shares during the last quarter. USS Investment Management Ltd grew its stake in Merck & Co., Inc. by 5.3% in the 1st quarter. USS Investment Management Ltd now owns 774,350 shares of the company’s stock valued at $45,609,000 after buying an additional 38,850 shares during the last quarter. Candriam Luxembourg S.C.A. grew its stake in Merck & Co., Inc. by 10.8% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 587,437 shares of the company’s stock valued at $31,997,000 after buying an additional 57,468 shares during the last quarter. Boston Research & Management Inc. grew its stake in Merck & Co., Inc. by 735.4% in the 1st quarter. Boston Research & Management Inc. now owns 42,548 shares of the company’s stock valued at $2,317,000 after buying an additional 37,455 shares during the last quarter. Finally, Oakworth Capital Inc. grew its stake in Merck & Co., Inc. by 10.9% in the 1st quarter. Oakworth Capital Inc. now owns 27,058 shares of the company’s stock valued at $1,592,000 after buying an additional 2,670 shares during the last quarter. Institutional investors own 72.31% of the company’s stock.

Shares of Merck & Co., Inc. stock opened at $72.21 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a fifty-two week low of $52.83 and a fifty-two week high of $72.89. The firm has a market capitalization of $193.64 billion, a price-to-earnings ratio of 17.10, a P/E/G ratio of 2.22 and a beta of 0.81.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.03. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. The firm had revenue of $10.47 billion during the quarter, compared to the consensus estimate of $10.28 billion. During the same period in the prior year, the firm earned $1.01 EPS. The business’s revenue was up 5.4% on a year-over-year basis. On average, equities research analysts expect that Merck & Co., Inc. will post 4.28 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, October 5th. Shareholders of record on Monday, September 17th were issued a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date of this dividend was Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 48.24%.

In other Merck & Co., Inc. news, VP Rita A. Karachun sold 5,000 shares of the stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $65.01, for a total value of $325,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Adam H. Schechter sold 107,360 shares of the stock in a transaction on Monday, September 17th. The shares were sold at an average price of $70.18, for a total transaction of $7,534,524.80. Following the completion of the sale, the executive vice president now directly owns 100,000 shares of the company’s stock, valued at $7,018,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 929,360 shares of company stock valued at $64,370,599. Insiders own 0.32% of the company’s stock.

MRK has been the topic of a number of research analyst reports. Bank of America raised their target price on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Zacks Investment Research upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research note on Monday, October 8th. Morgan Stanley set a $74.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, August 23rd. Jefferies Financial Group reiterated a “hold” rating and issued a $59.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, July 15th. Finally, SunTrust Banks reiterated a “buy” rating and issued a $77.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, August 16th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $70.24.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.